Stocktoria
Inhibikase Therapeutics, Inc. IKT
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-12-23
Inhibikase Therapeutics, Inc. statistics & valuation
Market cap$252.2M
P / B1.5×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | — | — | -7712.0% | -14686.2% | -476.2% |
| Net margin | — | — | -7304.7% | -14625.9% | -476.9% |
| FCF margin | — | — | -6947.9% | -14253.4% | -461.1% |
| Return on assets | -26.6% | -27.9% | -131.2% | -72.4% | -34.8% |
| Return on equity | -27.9% | -29.0% | -173.3% | -85.8% | -38.5% |
| Debt / equity | — | — | 0.03× | — | 0.01× |
| Current ratio | 21.70 | 26.37 | 4.13 | 6.59 | 10.47 |
| Revenue growth | — | -100.0% | 111.0% | -96.0% | 343.9% |
Source: SEC EDGAR filings · CIK 0001750149 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.